Brainstorm Cell, (BCLI) falls 0.65% in Active Trading on October 25 – Equities.com

Last Price$ Last TradeChange$ Change Percent %Open$ Prev Close$ High$ low$ 52 Week High$ 52 Week Low$ Market CapPE RatioVolumeExchange

BCLI - Market Data & News

Today, Brainstorm Cell Therapeutics, Inc. Incs (NASDAQ: BCLI) stock fell $0.02, accounting for a 0.65% decrease. Brainstorm Cell, opened at $3.05 before trading between $3.10 and $2.94 throughout Mondays session. The activity saw Brainstorm Cell,s market cap fall to $111,134,797 on 229,375 shares -above their 30-day average of 90,730.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has completed a Phase 3 pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). BrainStorm is also conducting an FDA-approved Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) completed dosing in December 2020, and topline results are expected by the end of the first quarter 2021.

Visit Brainstorm Cell Therapeutics, Inc.'s profile for more information.

Here's a trending selection from our newsletter, The Daily Fix, that captured readers' attention.Click hereto subscribe and get The Daily Fix delivered right to your inbox.

Restaurant Brands International Misses Revenue Estimates; Cites Staffing Shortage, COVID-19

Burger King and Tim Hortons are struggling with a staffing crunch and the Delta variant keeping coffee-loving office workers at home, causing parent Restaurant Brands International Inc (NYSE: QSR), to miss estimates for quarterly revenue on Monday.

U.S.-listed shares shed 4.4% as same-store sales at its Burger King, Tim Hortons and Popeyes chains came in below expectations in the third quarter.

[More]

Sustainable Shoe Maker Allbirds Seeks IPO Valuation North of $2 Billion

Sustainable shoe brand Allbirds Inc is eyeing a valuation exceeding $2 billion in its US initial public offering (IPO).

In its amended Form S-1 filed Monday, the company said it is offering about 19.23 million shares priced between $12 and $14 apiece. At the high end of that range, Allbirds would fetch gross proceeds of over $269 million.

[More]

Hertz Orders 100,000 Tesla Model 3 Vehicles; First Step Toward Electrifying Fleet

Hertz Global Holdings Inc (OTC: HTZZ) has placed an order for 100,000 Tesla Inc (NASDAQ: TSLA) electric cars, the first step in the rental car companys plan to electrify its fleet of a half million cars.

Starting in early November, the Florida-based company will offer Tesla Model 3 compact cars for rent at its airport and neighborhood locations in major US markets and certain European cities, Hertz announced Monday.

[More]

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Brainstorm Cell Therapeutics, Inc. and to follow the company's latest updates, you can visit the company's profile page here: Brainstorm Cell Therapeutics, Inc.'s Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE:The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Continued here:
Brainstorm Cell, (BCLI) falls 0.65% in Active Trading on October 25 - Equities.com